Physician profile
James M Hunt
NPI 1083811442
$159,758.29
in general payments reported to CMS, 2019-2025
42 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $12K · 2021: $23K · 2022: $14K · 2023: $20K · 2024: $21K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Honoraria: $15K · Food and Beverage: $6,907 · Travel and Lodging: $5,335 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,625.00 |
| Honoraria | $15,187.00 |
| Food and Beverage | $6,906.84 |
| Travel and Lodging | $5,334.98 |
| Education | $226.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $102,760.04 | 2019-2023 | Krystexxa, Tepezza |
| Amgen INC. | $47,215.87 | 2019-2025 | Krystexxa, Evenity, Tavneos |
| Abbvie INC. | $2,020.77 | 2019-2025 | |
| Janssen Biotech, INC. | $1,970.22 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,202.56 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $626.78 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $502.63 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $493.18 | 2020-2025 | |
| Pfizer INC. | $447.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $305.08 | 2020-2025 | Benlysta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.11 | 2019-2024 | Cyltezo, Ofev |
| Lilly USA, LLC | $287.11 | 2019-2023 | Taltz |
| Genzyme Corporation | $267.14 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $224.34 | 2019 | |
| Aurinia Pharma U.S., INC. | $170.93 | 2021-2024 | Lupkynis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.